ILIKOS Consulting Group, a Cyprus-based company that offers services to Contract Research Organisations (CROs) and life science companies, announced on Tuesday that it has partnered with Jordan Center for Pharmaceutical Research (JCPR), a pharmaceutical research facility in Jordan.
The partnership is aimed at highlighting the advantages in designing and executing BE/BA studies in Jordan and advancing innovative clinical research across the country.
Elias Sayias, ILIKOS founder and CEO, said: "With increasing global pressures on the generics industry, from regulatory shifts to rising development costs, it's critical to explore innovative and reliable solutions. Jordan's strategic position, combined with JCPR's extensive expertise, offer a compelling value proposition for sponsors navigating the challenges of modern drug development. Our goal is to support bridging cultural, regulatory and operational gaps to deliver cost-effective, high-quality outcomes."
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical